Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.